Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (223)	1/20/1998 9:02:00 AM
From: Apache Indian	Read Replies (1) \| Respond to of 1494

I am going to pick up some today, have already lost most of my investment on this stock, so I guess a few more bucks wont hurt. But looks like everybody is very optimistic about memantine, at least it should clear phase II, looks like even Nasdaq keeps extending NTII's listing for some reason. I dont think it met its previous requirement of the 1 $ bid till Jan. 15th to remain listed in the small cap mkt. Anyways, I'm going to bet on memantine and pick up a couple of thousand more, if the stock crosses 2 1/2, hey I'll be making money on this dog after all these years.

To: Dr. John M. de Castro who wrote (223)	1/20/1998 3:50:00 PM
From: Rudy Saucillo	Respond to of 1494

Thanks, John. Here are 2 additional abstracts supporting the role of memantine as a potential treatment for pathological pain. I'm "long" and looking forward to the upcoming Phase II results. Rudy Neurosci Lett 1995 Sep 29;198(2):115-118 Treatment with the NMDA antagonist memantine attenuates nociceptive responses to mechanical stimulation in neuropathic rats. Carlton SM, Hargett GL Systemic treatment with the N-methyl-D-aspartate (NMDA) antagonist memantine (MEM) resulted in a decrease in mechanical hyperalgesia and mechanical allodynia in neuropathic rats. Bolus injections of 5, 10 and 20 mg/kg MEM (i.p.) attenuated withdrawal responses following mechanical stimulation for up to 6 h post-injection while saline had no effect. A more remarkable effect was observed following chronic treatment with MEM via mini-osmotic pumps (8 mg/kg per h for 7 days, i.p.), in which nociceptive responses were decreased during treatment and remained depressed for 3 days post-treatment. These antinociceptive effects can be obtained at doses which do not produce motor dysfunction. The results of this study demonstrate that MEM has a therapeutic effect on mechanical hyperalgesia and allodynia and may be considered as an alternative treatment for pathological pain in the clinical setting. Neurosci Lett 1995 Feb 24;187(1):17-20 The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Eisenberg E, LaCross S, Strassman AM This study tested the prophylactic and therapeutic efficacy of memantine (1-amino-3,5-dimethyl-amandate), a clinically tested N-methyl-D-aspartate (NMDA) antagonist on thermal hyperalgesia in a rat model of painful mononeuropathy. Persistent hyperalgesia induced by chronic constrictive injury (CCI) to the sciatic nerve was significantly reduced for up to 14 days by prophylactic administration of memantine (3.0 mg/kg) via i.p. implanted osmotic micropumps for a period of 7 days. Therapeutic i.p. injections of memantine (10 mg/kg) given on post-injury days 7 and 14 completely reversed existing hyperalgesia for a short period of 1 h. These results provide evidence that memantine produces long-term prophylactic and short-term therapeutic effects on thermal hyperalgesia in a model of painful mononeuropathy.